Malignant pleural mesothelioma is an aggressive malignancy of the pleural surface,
predominantly caused by prior asbestos exposure. There is a global epidemic of malignant …

Guidelines for the diagnosis and treatment of malignant pleural mesothelioma - PMC Back to
Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage …

Purpose To provide evidence-based recommendations to practicing physicians and others
on the management of malignant pleural mesothelioma. Methods ASCO convened an …

PURPOSE This phase I study, which to our knowledge is the first-in-human study of this
kind, investigates the safety, tolerability, pharmacokinetics, and clinical activity of anetumab …

Background New biomarkers are needed to detect pleural mesothelioma at an earlier stage
and to individualize treatment strategies. We investigated whether fibulin-3 in plasma and …

Abstract On November 9 and 10, 2015, the International Conference on Mesothelioma in
Populations Exposed to Naturally Occurring Asbestiform Fibers was held at the University of …

BACKGROUND The primary objective of this study was to determine the safety and
maximum tolerated dose (MTD) of the antimesothelin immunotoxin SS1 (dsFv) PE38 …

Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that arises from the
mesothelial surface of the pleural and peritoneal cavities, the pericardium, and rarely, the …

Malignant pleural mesothelioma (MPM) is characterised by late-stage diagnosis and poor
prognosis. Currently, no screening tool is advocated and diagnosis is based on invasive …

Purpose: Malignant pleural mesothelioma (MPM) is an aggressive cancer associated with
poor prognosis. CRS-207 is a live-attenuated Listeria monocytogenes engineered to …